REPL
Replimune Group Inc
NASDAQ: REPL · HEALTHCARE · BIOTECHNOLOGY
$2.38
-7.39% today
Updated 2026-04-29
Market cap
$212.21M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.44
Dividend yield
—
52W range
$2 – $13
Volume
5.4M
Replimune Group Inc (REPL) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — | — | — |
| Cost of revenue | $122000.00 | $109000.00 | $148000.00 | $1.81M | $4.14M | $4.58M | $2.45M | $2.65M | $3.50M |
| Gross profit | $-122000.00 | $-109000.00 | $-148000.00 | $-1.81M | $-4.14M | $-4.58M | $-2.45M | $-2.65M | $-3.50M |
| Gross margin | — | — | — | — | — | — | — | — | — |
| R&D | $6.94M | $13.52M | $22.17M | $38.76M | $57.49M | $80.64M | $126.53M | $174.96M | $189.45M |
| SG&A | $2.71M | $5.71M | $8.77M | $16.55M | $23.20M | $38.77M | $50.55M | $59.81M | $72.18M |
| Operating income | $-9.65M | $-19.23M | $-30.95M | $-56.20M | $-82.76M | $-121.48M | $-177.08M | $-234.77M | $-261.63M |
| Operating margin | — | — | — | — | — | — | — | — | — |
| EBITDA | $-8.08M | $-16.85M | $-30.69M | $-52.58M | $-76.48M | $-114.41M | $-171.72M | $-227.77M | $-253.92M |
| EBITDA margin | — | — | — | — | — | — | — | — | — |
| EBIT | $-8.21M | $-16.96M | $-30.83M | $-53.11M | $-80.62M | $-118.98M | $-174.17M | $-232.85M | $-259.85M |
| Interest expense | $0.00 | $0.00 | $0.00 | $1.92M | $3.06M | $2.22M | $4.16M | $6.66M | $7.89M |
| Income tax | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-7.70M | $-19.70M | $-30.83M | $-52.63M | $-80.87M | $-118.04M | $-174.28M | $-215.79M | $-247.30M |
| Net income growth (YoY) | — | -155.7% | -56.5% | -70.7% | -53.7% | -46.0% | -47.7% | -23.8% | -14.6% |
| Profit margin | — | — | — | — | — | — | — | — | — |